A Multi-Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-Beta-1a 44mcg Tiw (Rebif) for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Trial Profile

A Multi-Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-Beta-1a 44mcg Tiw (Rebif) for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Minocycline (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms RECYCLINE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 12 Oct 2012 Primary endpoint 'Time-to-relapse' has not been met.
    • 14 Jul 2011 Planned end date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top